Based on the Telix Pharmaceuticals Ltd stock forecast from 0 analysts, the average analyst target price for Telix Pharmaceuticals Ltd is not available over the next 12 months. Telix Pharmaceuticals Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Telix Pharmaceuticals Ltd is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Telix Pharmaceuticals Ltd’s stock price was AUD 24.74. Telix Pharmaceuticals Ltd’s stock price has changed by +0.86% over the past week, +7.75% over the past month and +152.97% over the last year.
No recent analyst target price found for Telix Pharmaceuticals Ltd
No recent average analyst rating found for Telix Pharmaceuticals Ltd
Company Overview Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia. Read Less
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The comp...Read More
Frequently Asked Questions About Telix Pharmaceuticals Ltd (TLX:AU) Stock
Stock Target Advisor's fundamental analysis for Telix Pharmaceuticals Ltd's stock is Slightly Bullish .
Unfortunately we do not have enough data on TLX:AU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on TLX:AU's stock to indicate what its average analyst target is.
TLX:AU stock's Price/Earning ratio is 166.07.
Our analysis grades TLX:AU stock's Price / Earning ratio at F. This means that TLX:AU stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the AU exchange.
Based on this TLX:AU may be a overvalued for its sector.
The last closing price of TLX:AU's stock was AUD 24.74.
The most recent market capitalization for TLX:AU is AUD 8.34B.
Unfortunately we do not have enough analyst data on TLX:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Telix Pharmaceuticals Ltd's stock.
As per our most recent records Telix Pharmaceuticals Ltd has 0 Employees.
Telix Pharmaceuticals Ltd's registered address is 55 Flemington Road, North Melbourne, VIC, Australia, 3051.
You can get more information about it from Telix Pharmaceuticals Ltd's website at https://telixpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Telix Pharmaceuticals Ltd (TLX:AU) Stock
Stock Target Advisor's fundamental analysis for Telix Pharmaceuticals Ltd's stock is Slightly Bullish .
Unfortunately we do not have enough data on TLX:AU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on TLX:AU's stock to indicate what its average analyst target is.
TLX:AU stock's Price/Earning ratio is 166.07.
Our analysis grades TLX:AU stock's Price / Earning ratio at F. This means that TLX:AU stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the AU exchange.
Based on this TLX:AU may be a overvalued for its sector.
The last closing price of TLX:AU's stock was AUD 24.74.
The most recent market capitalization for TLX:AU is AUD 8.34B.
Unfortunately we do not have enough analyst data on TLX:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Telix Pharmaceuticals Ltd's stock.
As per our most recent records Telix Pharmaceuticals Ltd has 0 Employees.
Telix Pharmaceuticals Ltd's registered address is 55 Flemington Road, North Melbourne, VIC, Australia, 3051.
You can get more information about it from Telix Pharmaceuticals Ltd's website at https://telixpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TLX:AU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
